VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s...
CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to...
CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse...
CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr...
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary...
CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D...
CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company") (TSX:RVX), in partnership with EVERSANA™, today announced that the U.S. Food and Drug...
CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of Company’s US$6.0...
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “BET Protein Inhibition for Pulmonary...
CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), a global leader in the development of epigenetic therapeutics, today announced that Donald...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.005 | -8.33333333333 | 0.06 | 0.06 | 0.055 | 53745 | 0.05900826 | CS |
4 | -0.005 | -8.33333333333 | 0.06 | 0.06 | 0.05 | 86976 | 0.05692392 | CS |
12 | -0.01 | -15.3846153846 | 0.065 | 0.07 | 0.045 | 73347 | 0.05777849 | CS |
26 | 0.005 | 10 | 0.05 | 0.095 | 0.04 | 78925 | 0.06855122 | CS |
52 | -0.015 | -21.4285714286 | 0.07 | 0.095 | 0.04 | 58805 | 0.0665862 | CS |
156 | -0.475 | -89.6226415094 | 0.53 | 0.82 | 0.04 | 68414 | 0.17965541 | CS |
260 | -1.085 | -95.1754385965 | 1.14 | 1.53 | 0.04 | 65158 | 0.44853236 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관